Today: 14 June 2026
Synopsys Shares Up Ahead of Earnings; Wednesday in Focus for Next Direction
23 May 2026
2 mins read

Synopsys Shares Up Ahead of Earnings; Wednesday in Focus for Next Direction

New York, May 23, 2026, 11:05 EDT

Synopsys shares got a late-week boost, jumping 4.12% Friday to finish at $524.74. Investors added positions in the chip-design software firm ahead of a holiday week and the company’s upcoming earnings. The stock came back from early losses, ending the week up about 4.4% after falling on Monday and Tuesday.

Nasdaq is closed Monday, May 25, for Memorial Day, so there’s no U.S. cash trading until regular hours resume—9:30 a.m. to 4 p.m. Eastern—on the next trading day. Synopsys plans to post fiscal Q2 numbers after the bell on Wednesday, May 27. The earnings call starts at 5 p.m. Eastern.

Stocks got a boost from the broader market. The S&P 500 finished up 0.4% Friday, its eighth weekly gain in a row. The Nasdaq Composite gained 0.2% for the day and ended the week up 0.5%, according to the Associated Press.

Synopsys provides EDA software, used by engineers for chip design and verification, and licenses semiconductor IP, which are pre-made circuit blocks sold to customers. This year, Synopsys brings in Ansys, the engineering simulation software firm it picked up last year, for its first full fiscal year under the Synopsys umbrella.

Synopsys is looking for revenue of $2.225 billion to $2.275 billion and adjusted earnings of $3.11 to $3.17 a share for the quarter out next week. These adjusted numbers exclude acquisition amortization, stock compensation and restructuring charges. Back in February, CEO Sassine Ghazi said “AI continues to fuel robust system-level and semiconductor R&D.” CFO Shelagh Glaser pointed to “strong execution and financial discipline” in first-quarter numbers. Synopsys Investor Relations

Wall Street sentiment turned positive heading into the results. Goldman Sachs analyst James Schneider kept his Buy rating and held the $600 price target, according to TipRanks. Schneider said Synopsys appeared “relatively shielded from AI-related disruption” and stood to gain from more custom chip design orders. TipRanks

Traders also picked up shares in chip-design software stocks. Cadence Design Systems, the main listed EDA competitor to Synopsys, added 4.22% Friday to end at $373.59. That marked a third gain in a row, MarketWatch reported.

The trade faces some headwinds. In February, Reuters reported Synopsys was still contending with China export curbs, lower demand from a key foundry customer, and its IP business took a hit, with revenue there down over 6% in Q1. On the call, Glaser said China revenue, not counting Ansys, was down a bit from a year ago.

Ansys is another concern. Synopsys closed its about $35 billion deal in July 2025, saying it would let the company go wider in silicon design, IP, simulation and analysis. The company said the first joint features could arrive in the first half of 2026. Ghazi called it a “transformational milestone,” but investors now want to see if integration costs, debt and product overlap cut into earnings growth. Synopsys News Releases

Synopsys ended Friday with a market cap near $100.1 billion and a PE over 80, market data shows. There’s not much room if management turns cautious on China, chip IP demand, or its Ansys synergies in its outlook.

Narrow trading week coming up: markets are shut Monday, Tuesday is the only full session, and Synopsys reports after the close on Wednesday. For Synopsys, the focus has shifted. AI chip spending isn’t the question. Now it’s whether demand is strong and wide enough to back up the rally in the stock.

Stock Market Today

  • Parabilis Medicines Raises Over $845 Million In Upsized IPO And Regeneron Private Placement
    June 14, 2026, 11:27 AM EDT. Parabilis Medicines, a clinical-stage biopharmaceutical company, closed an upsized initial public offering (IPO) raising approximately $770.5 million by selling 38.525 million shares at $20 each. Shares began trading on Nasdaq under ticker PBLS. Concurrently, Regeneron Pharmaceuticals invested $75 million in a private placement at $18 per share. Combined, Parabilis secured around $845.5 million, contributing to over $1.2 billion raised in 2026 through financing and strategic deals. The company is developing Helicons, a novel therapy targeting previously undruggable proteins. Major banks including Leerink Partners and BofA Securities managed the offerings.

Latest articles

Becerra jumps ahead in California governor race, Trump-backed Hilton lags

Becerra jumps ahead in California governor race, Trump-backed Hilton lags

14 June 2026
Democrat Xavier Becerra leads Republican Steve Hilton by 21 points among registered California voters, according to a UC Berkeley IGS/Los Angeles Times poll, as official results confirm a November faceoff with Becerra at 28.1% and Hilton at 24.7%; Democrats’ registration edge gives Becerra “a huge advantage,” with results to be certified by July 10.
FuboTV gets Wall Street upgrade as NBCUniversal returns, World Cup fuels demand

FuboTV gets Wall Street upgrade as NBCUniversal returns, World Cup fuels demand

14 June 2026
fuboTV surged into focus after Wall Street Zen upgraded the stock to hold from sell, with MarketBeat showing a Moderate Buy consensus and $16.83 average price target, as investors weigh improved adjusted EBITDA, restored NBCUniversal channels, and World Cup streaming against falling subscriber numbers; FUBO last traded at $9.83 after Friday’s session.
Hyliion Shares Jump 43% As Navy Sea-Trial News Drives HYLN Higher
Previous Story

Hyliion Shares Jump 43% As Navy Sea-Trial News Drives HYLN Higher

AeroVironment Stock Watch: Navy Laser Test Puts AVAV Back in Drone-Defense Focus
Next Story

AeroVironment Shares Surge 10% Ahead of Holiday With Tuesday in Focus for AVAV

Go toTop